Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation

Boehringer Ingelheim

Status: Completed

Conditions: Atrial Fibrillation

Study type: Observational

Funder types: Industry

Identifiers

NCT02433366

1160.149

Details and patient eligibility

About

The key focus of this survey will be to collect data on physicians awareness of the content of the Pradaxa® Prescriber Guide and the extent to which risk awareness is communicated to patients. The data collected with atrial fibrillation patients will show if and how well this information is received and understood.

Full description

Purpose:

Enrollment: 1,213 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pradaxa® prescribers (cardiologists and primary care physicians)
• Patients with atrial fibrillation treated with Pradaxa®

Exclusion criteria

As defined in Summary of Product Characteristics for patients treated with Pradaxa®

Trial design

1,213 participants in 2 patient groups

Patients

Physicians